JP2025509343A5 - - Google Patents

Info

Publication number
JP2025509343A5
JP2025509343A5 JP2024553571A JP2024553571A JP2025509343A5 JP 2025509343 A5 JP2025509343 A5 JP 2025509343A5 JP 2024553571 A JP2024553571 A JP 2024553571A JP 2024553571 A JP2024553571 A JP 2024553571A JP 2025509343 A5 JP2025509343 A5 JP 2025509343A5
Authority
JP
Japan
Prior art keywords
administered
pharmaceutical composition
analog
antibody
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509343A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063869 external-priority patent/WO2023172917A1/en
Publication of JP2025509343A publication Critical patent/JP2025509343A/ja
Publication of JP2025509343A5 publication Critical patent/JP2025509343A5/ja
Pending legal-status Critical Current

Links

JP2024553571A 2022-03-07 2023-03-07 多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用 Pending JP2025509343A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317253P 2022-03-07 2022-03-07
US63/317,253 2022-03-07
PCT/US2023/063869 WO2023172917A1 (en) 2022-03-07 2023-03-07 Use of isatuximab in combination with other agents for the treatment of multiple myeloma

Publications (2)

Publication Number Publication Date
JP2025509343A JP2025509343A (ja) 2025-04-11
JP2025509343A5 true JP2025509343A5 (enExample) 2026-03-16

Family

ID=85800365

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553571A Pending JP2025509343A (ja) 2022-03-07 2023-03-07 多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用

Country Status (10)

Country Link
US (1) US20250177519A1 (enExample)
EP (1) EP4489766A1 (enExample)
JP (1) JP2025509343A (enExample)
KR (1) KR20250029015A (enExample)
CN (1) CN119486744A (enExample)
AU (1) AU2023231217A1 (enExample)
CA (1) CA3245572A1 (enExample)
IL (1) IL315471A (enExample)
MX (1) MX2024010925A (enExample)
WO (1) WO2023172917A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3154581B1 (en) * 2014-06-16 2019-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
US11221328B2 (en) * 2017-03-08 2022-01-11 Nantcell, Inc. Hypoxic NK cells and methods therefor
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
CN114867485A (zh) 2019-10-31 2022-08-05 全国儿童医院研究所 Cd38敲除的原代和扩增的人nk细胞的生成
PH12023550160A1 (en) * 2020-07-31 2023-09-18 Exelixis Inc Combinations for the Treatment of Cancer

Similar Documents

Publication Publication Date Title
ES2317620T3 (es) Fragmentos de gonadotropina corionica humana (hcg) como inmunorregulador.
US10953071B2 (en) Compositions and methods for treatment of intracellular damage and bacterial infection
CA2332817A1 (en) Il-6 antagonist peptides
SG172848A1 (en) Cyclosporine derivative for use in the treatment of hcv and hiv infection
ES2728405T3 (es) Tratamiento de la infección por virus de hepatitis delta
JPH04364133A (ja) 抗ｔｎｆ抗体の虚血症およびその随伴症状の処置用の医薬としての使用
KR20060120037A (ko) Ｈｃｖ 감염 치료용 병용 요법
EP0230574A2 (en) Pharmaceutical compositions against infections caused by LAV/HTLV III virus and the use thereof
US5250296A (en) Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
JP2022035920A5 (enExample)
Santini et al. Differentiation therapy of myelodysplastic syndromes: fact or fiction?
JPH07267874A (ja) Ｈｉｖ感染に対する組合せ化学療法
US20180243366A1 (en) Drug containing recombinant mistletoe lectins for treating malignant melanoma
JP4800194B2 (ja) 乾癬の治療薬を製造するためのカハラリド化合物の使用
US20220323423A1 (en) Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release
CA2141951C (en) Inhibition of retrovirus infection
RU2024129953A (ru) Применение изатуксимаба в комбинации с другими средствами для лечения множественной миеломы
Sakurai et al. Induction of tumor necrosis factor in mice by recombinant human macrophage colony‐stimulating factor
RU2690677C1 (ru) Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью
JPH0840888A (ja) ミエローマ系腫瘍抗癌剤
Lindner et al. Synergism of the malononitrilamides 279 and 715 with cyclosporine A in the induction of long‐term cardiac allograft survival
Mufazalova et al. Effects of T-activin and vitamin E on toxicity and antitumor activity of cyclophosphamide
EP3570849A1 (en) Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
US7368423B1 (en) Composition and method for treating chronic allograft rejection
EP0336958B1 (fr) Produit comprenant a titre de principes actifs: a) un peptide ayant une activite du type de celle de l'interferon gamma humain, b) l'hydroxyuree